NCT00248976

Brief Summary

The objective of this randomized trials is to evaluate, among coronary artery disease patients who have just had either angioplasty or stents, whether a novel intervention based on feedback of individualized risk profiles framed as the opportunity to reduce one's biological age is more effective after two years in reducing mortality and major cardiovascular morbidity (specifically, myocardial infarction, stroke, class II-IV angina, and severe ischemia) than the standard risk reduction approach, which is framed as one's opportunity to reduce future risk. The novel strategy is based on the theory of net-present value and is tested in coronary artery disease patients who have a high risk of adverse outcomes by two years.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
660

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Apr 1999

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 1999

Completed
5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 29, 2004

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 29, 2004

Completed
1.6 years until next milestone

First Submitted

Initial submission to the registry

November 3, 2005

Completed
1 day until next milestone

First Posted

Study publicly available on registry

November 4, 2005

Completed
Last Updated

October 29, 2018

Status Verified

October 1, 2018

Enrollment Period

5 years

First QC Date

November 3, 2005

Last Update Submit

October 25, 2018

Conditions

Keywords

AngioplastyMotivating behavior changeReducing risk factorsEnhancing quality of lifeImproving treatment outcomes

Outcome Measures

Primary Outcomes (5)

  • Mortality

  • Myocardial Infarction

  • Angina

  • Severe ischemia on non-invasive testing

  • Stroke

Secondary Outcomes (3)

  • a. To determine whether patients who receive the net-present value intervention have more improvements in their risk factor profile than those in the control group at two years.

  • b. To determine whether the net-present value intervention will enable patients to sustain behavioral change over the long-term.

  • c. To determine whether the net-present value intervention will improve overall functional status and prevent further disability.

Study Arms (2)

1

NO INTERVENTION

This is the control group, which will be monitor. No intervention will be delivered to this group.

2

EXPERIMENTAL

This group received the experimental intervention. This is an intervention based on feedback of individualized risk profiles framed as the opportunity to reduce one's biologic age. Net-present value of individual health behaviors in years.

Behavioral: Net-present value of individual health behaviors in years

Interventions

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • All patients undergoing coronary artery catheterization who are found to have at least single vessel stenosis and who have had revascularization with angioplasty or coronary artery stenting will be eligible for enrollment. Patients must be able to provide informed consent within the one week after the procedures.

You may not qualify if:

  • Patients must be verbally fluent in English. To ascertain this, we ask the patient to rate their fluency on a scale of 1-10 (with 10 as best), and if the score is 7 or more, they are approached for consent. The patient must be able to provide their own consent without translation.
  • Enrollment in other trials designed to modify post-procedure behaviors.
  • Patients who refuse to participate will be excluded.
  • If at any time prior to enrollment in the study, the patient's cardiologist determines that the patient should not participate in this study, the patient will not be enrolled in the trial.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

New York Presbyterian College-Weill Medical Center

New York, New York, 10021, United States

Location

Study Officials

  • Mary E Charlson, MD

    Weill Medical College of Cornell University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
OTHER
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
The William T. Foley Distinguished Professor in Medicine

Study Record Dates

First Submitted

November 3, 2005

First Posted

November 4, 2005

Study Start

April 1, 1999

Primary Completion

March 29, 2004

Study Completion

March 29, 2004

Last Updated

October 29, 2018

Record last verified: 2018-10

Locations